Overview Study of DS-1123a in Advanced Solid Tumours Status: Completed Trial end date: 2017-11-01 Target enrollment: Participant gender: Summary This is an open-label study to evaluate the safety, tolerability, and pharmacokinetics of DS-1123a in Japanese subjects with advanced solid tumors. Phase: Phase 1 Details Lead Sponsor: Daiichi Sankyo Co., Ltd.